Understanding and treating side effects from cancer immunotherapy
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
This work aims to better understand and find new ways to treat the immune-related side effects that some people experience when undergoing cancer immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11093975 on NIH RePORTER |
What this research studies
Cancer immunotherapies, called checkpoint inhibitors, are powerful treatments, but they can sometimes cause serious immune-related side effects. Currently, steroids are often used to treat these side effects, but they can make the cancer treatment less effective. This project looks into the specific ways these side effects develop in the body, focusing on conditions like arthritis, colitis, and lung inflammation. By studying both patient information and advanced lab models, we hope to uncover the underlying causes of these reactions. Our goal is to find new, more targeted treatments that can manage side effects without compromising the cancer-fighting benefits of immunotherapy.
Who could benefit from this research
Good fit: This research is relevant for patients with advanced cancer who are receiving immune checkpoint inhibitors and experience immune-related side effects such as arthritis, colitis, or pneumonitis.
Not a fit: Patients not receiving immune checkpoint inhibitors or those without immune-related side effects would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for immune-related side effects that are more effective and do not interfere with the cancer-fighting power of immunotherapy.
How similar studies have performed: While immune checkpoint inhibitors are established, understanding the specific mechanisms of their side effects and developing targeted therapies is an ongoing area of active research, with some prior work identifying immune cell signatures.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Nurieva, Roza Insafetdinovna — University of Tx Md Anderson Can Ctr
- Study coordinator: Nurieva, Roza Insafetdinovna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.